Valuations make buyers out of biotechs once seen as takeover targets

05/10/2013 | Reuters

Rising stock valuations due to promising drug data have transformed biotech drugmakers from acquisition targets into potential buyers, analysts said. Aside from rich valuations, easy access to financing and low interest rates provided alternatives to funding research and commercialization, a health banker said.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT